|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2004-8-3
|
|
pubmed:abstractText |
Cyclosporine (INN, ciclosporin) increases the systemic exposure of all statins. Therefore rosuvastatin pharmacokinetic parameters were assessed in an open-label trial involving stable heart transplant recipients (> or =6 months after transplant) on an antirejection regimen including cyclosporine. Rosuvastatin has been shown to be a substrate for the human liver transporter organic anion transporting polypeptide C (OATP-C). Inhibition of this transporter could increase plasma concentrations of rosuvastatin. Therefore the effect of cyclosporine on rosuvastatin uptake by cells expressing OATP-C was also examined.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0009-9236
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
76
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
167-77
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15289793-Administration, Oral,
pubmed-meshheading:15289793-Adult,
pubmed-meshheading:15289793-Aged,
pubmed-meshheading:15289793-Animals,
pubmed-meshheading:15289793-Area Under Curve,
pubmed-meshheading:15289793-Biological Availability,
pubmed-meshheading:15289793-Cells, Cultured,
pubmed-meshheading:15289793-Cyclosporine,
pubmed-meshheading:15289793-Dose-Response Relationship, Drug,
pubmed-meshheading:15289793-Drug Administration Schedule,
pubmed-meshheading:15289793-Drug Interactions,
pubmed-meshheading:15289793-Female,
pubmed-meshheading:15289793-Fluorobenzenes,
pubmed-meshheading:15289793-Follow-Up Studies,
pubmed-meshheading:15289793-Graft Rejection,
pubmed-meshheading:15289793-Graft Survival,
pubmed-meshheading:15289793-Heart Transplantation,
pubmed-meshheading:15289793-Humans,
pubmed-meshheading:15289793-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:15289793-Male,
pubmed-meshheading:15289793-Middle Aged,
pubmed-meshheading:15289793-Oocytes,
pubmed-meshheading:15289793-Pyrimidines,
pubmed-meshheading:15289793-Sulfonamides,
pubmed-meshheading:15289793-Transplantation Immunology,
pubmed-meshheading:15289793-Treatment Outcome,
pubmed-meshheading:15289793-Xenopus
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
|
|
pubmed:affiliation |
AstraZeneca, Wilmington, Del, USA. steven.simonson@astrazeneca.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Controlled Clinical Trial
|
